In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma

Keller Lab

Mechanism-based Cancer Therapies

Our utmost goal is to identify and target crucial cancer cell vulnerabilities while sparing normal tissue. From discovery approaches to validation and preclinical testing. Aiming for clinical application.

Cancer originates from normal cells through genetic and epigenetic alterations. By employing forward genomic screening we start from a known gene mutation or cancer-associated condition and investigate the path that results in a manifest malignancy. Major further focus areas of the lab include: oncoprotein-induced disturbance of post-translational protein modifications, in particular SUMOylation, and sensing of DNA damage; constitutively activated B-cell receptor and chemokine receptor signaling; and molecular cancer imaging and theranostics.

Team

Group Leader

Prof. Dr. med. Ulrich Keller

Team

Stefanos Bamopoulos, Dr. med., Clinician Scientist                                       

Francis Baumgartner, Dr. med., Clinician Scientist 

Uta Demel, Dr. med., Clinician Scientist

Stefan Habringer, Dr. med. Dr. univ., Clinician Scientist, Team Leader

Maximilian Holz, MD Student

Konstandina Isaakidis, M.Sc., Lab Manager

Kaiting Jiang, MD Student

Hazal Köse, PhD Student

Hongyu Liu, Dr. rer. medic., Staff Scientist

Anna Meurer, Clinician Scientist

Markus Schick, Dr. rer. nat., Associated Scientist

Laura Schmalbrock, Dr. med., Clinician Scientist

Daniel Steiert, PhD Student

Isabelle Träger, MD Student

Sara Uhan, PhD Student

Philine Wegner, PhD Student

Matthias Wirth, PD Dr. rer. nat., Scientist, Team Leader

Yan Zhao, Dr. rer. nat , Scientist

Chuanbing Zang, Dr. rer. medic., Staff Scientist

Laura Ferreiro Vazquez, PhD Student

Amelie Gasper, PhD Student

Luca Hummel, PhD Student

Paul Jung, Clinician Scientist

Michael Korenkov, Clinician Scientist

Felix Stuckenbrok, PhD Student                                       

Antonia Busse, PD Dr. med., Clinician Scientist, Team Leader, Sub-PI

Sarah Al-Tabatabaee, MD Student (Busse group)

Nese Cakmak, Dr. rer. nat., Scientist (Busse group)

Cäcilia Freund, Technical Assistant (Busse group)

Corinna Grunert, Dr. rer. nat., Scientist (Busse group)

Paula Mühlschlegel, MD Student (Busse group)

Luisa Ohlmeier PhD Student (Busse group)

Simone Rhein, Dr. rer. nat., Scientist (Busse group; affiliation EPO GmbH)

Jon Hergueta Sanchez PhD Student (Busse group)

Emina Sivro, PhD Student (Busse group)

Stefanos Timioloitis, PhD Student (Busse group)

Sarvenaz Yaghobramzi, Physician (Busse group)

Melanie Winiarski, Technical Assistant (Busse group)

People wearing lab coats sitting in an auditorium

Research

Currently, the Keller Group focuses on the following research projects:
Myc-associated cancer biology
 
Myc-associated cancer biology
Functional genomic screening
 
Functional genomic screening
Aberrant Ub/SUMO activity in cancer
 
Aberrant Ub/SUMO activity in cancer
Chemokine receptor signaling
 
Chemokine receptor signaling
Functional imaging and theranostics
 
Functional imaging and theranostics

Publications

/ Ann Rheum Dis

Teclistamab in relapsed systemic sclerosis after autologous haematopoietic stem cell transplantation

  • E. Siegert
  • R. Biesen
  • M. Dzamukova
  • C. Furth
  • M. Probst
  • F. Doellinger
  • T. Walter-Rittel
  • A. Fleischmann
  • A. Wilhelm
  • A.E. Beenken
  • E. Wiebe
  • A.C. Pecher
  • J. Henes
  • S. Florian
  • D. Simon
  • A. Kleyer
  • G.R. Burmester
  • U. Keller
  • J. Krönke
  • G. Krönke
  • T. Alexander
/ Eur J Cancer

Characterizing uveal melanoma patients with peritoneal metastases: a retrospective single-center analysis

  • S. Rosnev
  • C.A. Peuker
  • I. Piwonski
  • J. Ihlow
  • S. Leyvraz
  • J. Klingberg
  • D. Horst
  • M. Joosten
  • M. Möbs
  • A.M. Joussen
  • M. de Bucourt
  • U. Keilholz
  • U. Keller
  • S. Ochsenreither
  • S.M. Rittig
/ Nat Methods

Segment anything for microscopy

  • A. Archit
  • L. Freckmann
  • S. Nair
  • N. Khalid
  • P. Hilt
  • V. Rajashekar
  • M. Freitag
  • C. Teuber
  • M. Spitzner
  • C. Tapia Contreras
  • G. Buckley
  • S. von Haaren
  • S. Gupta
  • M. Grade
  • M. Wirth
  • G. Schneider
  • A. Dengel
  • S. Ahmed
  • C. Pape
/ J Neurooncol

Clinical characteristics and outcomes in leptomeningeal disease with or without brain metastasis: insights from an explorative data analysis of the Charité LMD registry

  • D. Wasilewski
  • C. Eitner
  • R. Ates
  • S. Murad
  • Z. Shaked
  • J.A. Steinle
  • A. Wetzel-Yalelis
  • T.A. Sargut
  • J. Rösler
  • M.A. Samman
  • P. Truckenmüller
  • R. Mertens
  • D. Kroneberg
  • A. Kowski
  • H. Radbruch
  • D. Capper
  • F. Ehret
  • S. Roohani
  • N. Frost
  • J. Nawabi
  • J. Onken
  • M. Schlaak
  • J.U. Blohmer
  • U. Pelzer
  • U. Keller
  • J. Sehouli
  • P. Vajkoczy
  • U. Keilholz
  • M. Misch
/ JACC CardioOncol

Growth differentiation factor-15: a promising biomarker and target in cancer patients

  • M. Anker
  • L. Bullinger
  • U. Keller
  • M.S. Khan
/ Haematologica

A phase I study of MAGE-A1-targeted T1367 T-cell receptor-based cell therapy in patients with advanced multiple myeloma

  • J. Krüger
  • M. Obenaus
  • I.W. Blau
  • D. Hoser
  • M. Vaegler
  • H. Rauschenbach
  • I. Anagnostopoulos
  • K. Jöhrens
  • V. Scheuplein
  • E. Kieback
  • J. Böhme
  • A.C. Von Brünneck
  • J. Krönke
  • A. Busse
  • G. Willimsky
  • T. Blankenstein
  • A. Pezzutto
  • U. Keller
  • A. Nogai
/ Clin Chem Lab Med

Simplified preanalytical laboratory procedures for therapeutic drug monitoring (TDM) in patients treated with high-dose methotrexate (HD-MTX) and glucarpidase

  • F.L. Knörnschild
  • S. Liebig
  • P. Kießling
  • M. Prpic
  • T. Kim
  • U. Keller
  • K. Kappert
  • S. Schwartz
  • A. Jahic
/ Blood Adv

Safety and efficacy of glofitamab for relapsed/refractory large B-cell lymphoma in a multinational real-world study

  • E. Shumilov
  • R. Wurm-Kuczera
  • A. Kerkhoff
  • M. Wang
  • T. Melchardt
  • U. Holtick
  • U. Bacher
  • P.B. Staber
  • P. Mazzeo
  • C. Leng
  • D. Böckle
  • A.S. Hölscher
  • J. Kauer
  • N. Rotter
  • V. Vucinic
  • J.D. Rudzki
  • D. Nachbaur
  • V.L. Bücklein
  • U. Schnetzke
  • I. Krämer
  • K. Wille
  • A. Hasse
  • B. von Tresckow
  • M. Hänel
  • C. Koenecke
  • G.F. Velazquez
  • A. Viardot
  • C. Schmid
  • L. Thurner
  • D. Wolf
  • M. Subklewe
  • M. Dreyling
  • P. Dreger
  • S. Dietrich
  • U. Keller
  • U. Jäger
  • R. Greil
  • T. Pabst
  • G. Lenz
  • B. Chapuy
/ Leuk Res

In vitro testing of drug response in primary multiple myeloma cells using a microwell-based technology

  • J. Krüger
  • I.W. Blau
  • O. Blau
  • A. Bettelli
  • L. Rocchi
  • M. Bocchi
  • J. Krönke
  • L. Bullinger
  • U. Keller
  • A. Nogai
/ Eur J Heart Fail

New cardiovascular biomarkers in patients with advanced cancer – a prospective study comparing MR-proADM, MR-proANP, copeptin, high-sensitivity troponin T and NT-proBNP

  • M.S. Anker
  • L.C. Lück
  • M.S. Khan
  • J. Porthun
  • S. Hadzibegovic
  • A. Lena
  • U. Wilkenshoff
  • P. Weinländer
  • R. Evertz
  • M. Totzeck
  • A.A. Mahabadi
  • T. Rassaf
  • S.D. Anker
  • L. Bullinger
  • U. Keller
  • M. Karakas
  • U. Landmesser
  • J. Butler
  • S. von Haehling

Funding

  • Berlin Institute of Health (BIH)
  • Berliner Krebsgesellschaft
  • Bundesamt für Risikobewertung (BfR)
  • Bundesministerium für Bildung und Forschung (BMBF)
  • Deutsche Forschungsgemeinschaft (DFG)
  • Deutsche Krebshilfe
  • Else Kröner Fresenius Stiftung (EKFS)
  • German Cancer Consortium (DKTK)
  • Sonnenfeld-Stiftung
  • Stiftung Charité
  • Wilhelm-Sander-Stiftung

Research Topics